Inflammatory Disease Markers Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update
Inflammatory Disease Markers Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update
Summary
GlobalData's Medical Devices sector report, “Inflammatory Disease Markers Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2024 Update provides comprehensive information about the Inflammatory Disease Markers pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
Inflammatory Disease Markers are antigen/antibodies that detect specific antigen/antibodies produced by bone, cartilage or any other inflammatory disease activity.
Note:Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope
Extensive coverage of the Inflammatory Disease Markers under development
The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
The report reviews the major players involved in the development of Inflammatory Disease Markers and list all their pipeline projects
The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
The report provides key clinical trial data of ongoing trials specific to pipeline products
Recent developments in the segment / industry
Reasons to Buy
The report enables you to -
Formulate significant competitor information, analysis, and insights to improve R&D strategies
Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
Identify and understand important and diverse types of Inflammatory Disease Markers under development
Develop market-entry and market expansion strategies
Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
In-depth analysis of the product’s current stage of development, territory and estimated launch date
Introduction
Inflammatory Disease Markers Overview
Products under Development
Inflammatory Disease Markers - Pipeline Products by Stage of Development
Table Inflammatory Disease Markers - Pipeline Products by Stage of Development
Table Inflammatory Disease Markers - Pipeline Products by Stage of Development
Inflammatory Disease Markers - Pipeline Products by Segment
Table Inflammatory Disease Markers - Pipeline Products by Segment
Table Inflammatory Disease Markers - Pipeline Products by Segment
Inflammatory Disease Markers - Pipeline Products by Territory
Table Inflammatory Disease Markers - Pipeline Products by Territory
Table Inflammatory Disease Markers - Pipeline Products by Territory
Inflammatory Disease Markers - Pipeline Products by Regulatory Path
Table Inflammatory Disease Markers - Pipeline Products by Regulatory Path
Table Inflammatory Disease Markers - Pipeline Products by Regulatory Path
Inflammatory Disease Markers - Pipeline Products by Estimated Approval Date
Table Inflammatory Disease Markers - Pipeline Products by Estimated Approval Date
Table Inflammatory Disease Markers - Pipeline Products by Estimated Approval Date
Table Molecular Diagnostic Test - Rheumatoid Arthritis - Prospective, Multi-Center, Observational, Whole Blood Specimen Collection Study in Participants with Rheumatoid Arthritis with Inadequate Response or Intolerance to bDMARD or tsDMARD +/csDMARD Changing Treatment to a bDMARD or tsDMARD Treatment +/- csDMARD
Arizona State University Company Overview
Arizona State University Pipeline Products & Ongoing Clinical Trials Overview
Table Arizona State University Pipeline Products & Ongoing Clinical Trials Overview
Table Diagnostic Test - Rheumatoid Arthritis - Product Status
Table Diagnostic Test - Rheumatoid Arthritis - Product Description
AXO Science SAS Company Overview
AXO Science SAS Pipeline Products & Ongoing Clinical Trials Overview
University of Newcastle Pipeline Products & Ongoing Clinical Trials Overview
Table University of Newcastle Pipeline Products & Ongoing Clinical Trials Overview
Table Blood-Based Diagnostic Test - Endometriosis - Product Status
Table Blood-Based Diagnostic Test - Endometriosis - Product Description
University of Oxford Company Overview
University of Oxford Pipeline Products & Ongoing Clinical Trials Overview
Table University of Oxford Pipeline Products & Ongoing Clinical Trials Overview
Table Biomarker Based Assay - Rheumatoid Arthritis - Product Status
Table Biomarker Based Assay - Rheumatoid Arthritis - Product Description
University of Rochester Company Overview
University of Rochester Pipeline Products & Ongoing Clinical Trials Overview
Table University of Rochester Pipeline Products & Ongoing Clinical Trials Overview
Table PBMC-Based Companion Diagnostic Test - Product Status
Table PBMC-Based Companion Diagnostic Test - Product Description
University of Warwick Company Overview
University of Warwick Pipeline Products & Ongoing Clinical Trials Overview
Table University of Warwick Pipeline Products & Ongoing Clinical Trials Overview
Table Diagnostic Test - Arthritis - Product Status
Table Diagnostic Test - Arthritis - Product Description
University Rovira i Virgili Company Overview
University Rovira i Virgili Pipeline Products & Ongoing Clinical Trials Overview
Table University Rovira i Virgili Pipeline Products & Ongoing Clinical Trials Overview
Table CD-Medics Test - RA - Product Status
Table CD-Medics Test - RA - Product Description
Inflammatory Disease Markers- Recent Developments
Aug 01, 2024: Geneoscopy's Novel Stool-Based RNA Platform Shows High Accuracy in Monitoring Crohn's Disease
Jul 30, 2024: Scipher Medicine Launches a New Approach to Discover Treatment-Response-Predicting Biomarkers for Complex Diseases
Jul 02, 2024: Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, July 24, 2024
Jun 24, 2024: Recent Aga Clinical Practice Guideline Acknowledges That Individuals Who May Be at Increased Risk of Progression to Esophageal Cancer Might Be Identified Using Tissue-Based Biomarkers, Particularly Castle Biosciences' Tissuecypher Test
Jun 17, 2024: GENFIT: New EASL-EASD-EASO Clinical Practice Guidelines for MASLD Include NIS2+ as Key Tool for Detecting At-Risk MASH
Jun 17, 2024: Thermo Fisher Scientific Showcases Clinical Research Innovation at DIA Annual Meeting
May 16, 2024: Oxford Biodynamics and King's College London Collaborate to Develop EpiSwitch Prognostic and Predictive Biomarkers for Best Prevention of Rheumatoid Arthritis Following the APIPPRA Trial
May 16, 2024: Taking Cytokine Testing by Storm: Automated 7-Test Inflammation Panel from Siemens Healthineers Offers Faster Insights, More Information
May 07, 2024: Siemens Healthineers on Track to Meet Fiscal Year 2024 Targets After Second Quarter
Mar 18, 2024: Siemens Healthineers Intends to Close Fast Track Diagnostics
Feb 21, 2024: Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024
Jan 29, 2024: Siemens Healthcare Diagnostics Receives FDA 510(k) Clearance for Atellica CH High Sensitivity C-Reactive Protein 2 Assay
Jan 03, 2024: Myriad Genetics to Present at 42nd Annual J.P. Morgan Healthcare Conference
Jan 02, 2024: Bio-Rad's Management to Host Investor Meetings at J.P. Morgan's 42nd Annual Healthcare Conference
Dec 20, 2023: Siemens Healthcare Diagnostics Receives 510(k) Clearance For CardioPhase hsCRP Assay
Dec 06, 2023: GENFIT Announces Publication in the Journal of Hepatology on the Accurate Performance of NIS2+ as a Screening Tool for the Enrollment of Patients in MASH Clinical Trials
Nov 28, 2023: Thermo Fisher Scientific Prices Offering Of $2.5 Bln Of Senior Notes
Nov 16, 2023: Non-Invasive Paper Chip Developed To Diagnose Inflammation and Infection
Sep 26, 2023: GENFIT Announces Publication in Nature Medicine Confirming the Performance of its NASH Diagnostic Technology
Aug 28, 2023: Bio-Rad to Participate in Fireside Chat During Wells Fargo's 2023 Healthcare Conference
Aug 17, 2023: Myriad Genetics to Host Investor Day on September 19, 2023
Aug 16, 2023: LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 24